Capricor Therapeutics (NASDAQ:CAPR) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.21, Fidelity Earnings reports. Capricor Therapeutics had a negative net margin of 936.22% and a negative return on equity of 225.30%. The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.22 million.
Shares of NASDAQ:CAPR traded down $0.28 on Wednesday, hitting $3.47. 400 shares of the company were exchanged, compared to its average volume of 2,308,201. The firm’s 50 day moving average price is $4.14. Capricor Therapeutics has a one year low of $2.53 and a one year high of $12.30. The stock has a market capitalization of $13.39 million, a price-to-earnings ratio of -0.67 and a beta of 1.69.
Several research analysts have recently issued reports on the stock. ValuEngine upgraded shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Finally, HC Wainwright boosted their price objective on shares of Capricor Therapeutics from $3.50 to $12.40 and gave the stock a “buy” rating in a report on Monday, July 15th. Three research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $5.63.
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Story: Trading Ex-Dividend
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.